🔍

Torrent Pharmaceuticals Limited (TORNTPHARM)

₹4,558.90 -0.55% last close, 16 Oct

📊 NSE: TORNTPHARM 🏢 Pharmaceuticals - Indian - Formulations 📢 Latest filing: 07 Oct 2026 📝 Analysis written: 14 Dec 2025

Q2 FY27 results

📅 Next results: 23 Oct 2026 (board meeting)

Torrent Pharmaceuticals Limited's board meets on 23 Oct 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Torrent Pharmaceuticals' revenue was ₹4,921 Cr (+54.8% year on year, +17.3% on the previous quarter), and net profit ₹566 Cr (+3.3% year on year); the operating margin was 33.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹4,921	+54.8%	+17.3%
Operating profit	₹1,664	+61.2%	+22.7%
Net profit	₹566	+3.3%	+55.5%
EPS (₹)	14.87	-8.2%	+38.2%
Operating margin	33.8%	—	—

Full quarterly financials → Results calendar →

TORNTPHARM delivery percentage and open interest

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 62.71% of the TORNTPHARM shares traded on NSE were taken to delivery, against the stock's own 20-session average of 61.94%. That is close to its usual level. In TORNTPHARM futures, open interest rose 0.15% while the futures price fell 0.81%: short buildup (new short positions).

62.71%Delivery, 16 Oct

61.94%Own 20-session average

0.6×Volume vs its average

+0.15%Futures open interest

₹4,558.90NSE close · -0.55%

Delivery in the last 5 sessions: 65.3% · 61.5% · 63.1% · 64.3% · 62.7%

Delivery across the market →F&O open interest →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

India Ratings Revises Torrent Pharma's Outlook to Positive, Affirms IND AA+ Rating

🟢 POSITIVE ⭐ 9/10

OTHER 📅 07 Oct 2026, 07:32 PM

India Ratings and Research has affirmed Torrent Pharmaceuticals' credit rating at IND AA+ while revising the outlook from Stable to Positive for its existing banking facilities, issuer rating, and Non-Convertible Debentures (NCDs). The agency also affirmed and assigned an IND A1+ rating for existing and proposed Commercial Paper. This outlook upgrade reflects strengthening operational resilience and debt-servicing capabilities across its Rs 14,277 Cr debt base. Torrent Pharma generated TTM revenue of Rs 15,723 Cr and net profit of Rs 2,156 Cr with an operating margin of 33.0%.

Outlook on banking facilities, issuer rating, and NCDs revised from Stable to Positive at IND AA+
Commercial Paper rating affirmed and assigned at IND A1+ for existing and proposed limits
Positive outlook supports cost of borrowing on current total debt of Rs 14,277 Cr (D/E: 1.69)
Announcement dated October 07, 2026 under Regulation 30 of SEBI LODR

💡 Track subsequent credit rating reports for potential formal upgrades to AAA, and monitor upcoming quarterly interest expense trends alongside integration milestones of acquisitions.

Torrent Pharma Raises Torrent Urja 27 Stake Investment to ₹11.88 Cr for Captive Green Power

🟡 NEUTRAL ⭐ 3/10

OTHER 📅 28 Sep 2026, 12:03 PM

Torrent Pharmaceuticals has executed an amendment agreement to enhance its investment in Torrent Urja 27 Private Limited from ₹7.92 Cr to ₹11.88 Cr to acquire a 26% equity stake. The increase in investment is driven by an expansion in the captive hybrid (solar and wind) power project's capacity in Gujarat. Torrent Urja is a related party and step-down subsidiary of the company's holding entity, with completion expected in 18 to 21 months. Given Torrent Pharma's annual revenue of ₹15,723 Cr, the ₹11.88 Cr investment represents less than 0.1% of revenue and is financially immaterial.

Investment enhanced from INR 7,91,93,400 to INR 11,87,90,100
Acquisition of 26% equity stake (1,18,79,010 Class A Equity Shares at ₹10 each)
Target is a captive hybrid (Solar + Wind) power SPV in Gujarat
Indicative completion timeline is 18 to 21 months

💡 Track the 18 to 21 month operational timeline of the captive power project to gauge long-term power cost efficiencies, alongside quarterly operational margins.

Torrent Pharma Schedules Investor Meets from Sept 17 to Sept 21, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Sep 2026, 09:28 PM

Torrent Pharmaceuticals Limited has scheduled participation in multiple institutional investor conferences between September 17 and September 21, 2026. The company will attend the Jefferies India Forum on September 17 in Gurgaon, followed by the Kotak Healthcare Forum on September 18 and the JP Morgan India Conference on September 21 in Mumbai. The meetings will encompass group and one-on-one formats. This is a routine investor interaction schedule disclosure under SEBI LODR Regulation 30.

Participation in Jefferies India forum 2026 scheduled for 17-Sep-26 in Gurgaon
Attendance at Kotak Healthcare Forum 2026 set for 18-Sep-26 in Mumbai
Participation in JP Morgan India Conference scheduled for 21-Sep-26 in Mumbai
Format includes both group and one-on-one investor interactions

💡 Track subsequent post-meet disclosures or investor presentations on the stock exchanges for any updates on capital allocation or business strategy.

Torrent Pharma Shareholders Approve Shanti Ekambaram's Appointment with 99.98% Majority

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 07 Sep 2026, 08:03 PM

Torrent Pharmaceuticals announced the scrutiny results of its postal ballot completed on September 6, 2026. Shareholders approved the Special Resolution for appointing Shanti Ekambaram as an Independent Director with an overwhelming 99.98% votes in favor (34,13,59,869 votes). Only 81,679 votes (0.02%) were cast against the resolution out of 34,14,41,548 net valid votes. This concludes the formal regulatory approval process for strengthening the company's board governance.

Appointment of Shanti Ekambaram as Independent Director approved by 99.98% votes in favor
Total valid votes cast: 34,14,41,548 across 1,711 voting members
Only 54 members voted against the resolution (81,679 votes or 0.02%)
E-voting concluded at 5:00 pm on September 6, 2026

💡 This is a routine governance update; investors should continue tracking core operational drivers such as integration progress of JB Chemicals and USFDA compliance across Dahej and Indrad facilities.

Torrent Pharma to Participate in Emkay - Confluence 2026 on August 14

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Aug 2026, 04:19 PM

Torrent Pharmaceuticals has announced its participation in the 'Emkay - Confluence 2026' investor conference scheduled for August 14, 2026, in Mumbai. The company will engage in both group and one-on-one meetings with institutional investors. This is a standard procedural disclosure under SEBI Regulation 30. Given the company's large market capitalization of Rs 165,368 Cr, such institutional interactions are routine for maintaining investor relations.

Investor meeting scheduled for 14-Aug-26 in Mumbai.
Format includes both Group and One-on-One interactions with institutional investors.
Announcement filed on 11-Aug-26, providing 3 days advance notice.
Company maintains a high TTM revenue base of Rs 13,980 Cr and OPM of 32.6%.

💡 Investors should monitor the exchange for any post-meet presentations or transcripts that may provide updates on the JB Chemicals integration and US market growth strategies.

70 ESG Rating Assigned to Torrent Pharmaceuticals by NSE Sustainability Ratings

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Aug 2026, 02:51 PM

Torrent Pharmaceuticals has been assigned an Environmental, Social, and Governance (ESG) rating of 70 by NSE Sustainability Ratings and Analytics Limited, a SEBI-registered provider. This rating serves as an independent assessment of the company's sustainability practices. While the score provides transparency for institutional investors, it does not impact the company's current TTM revenue of ₹13,980 Cr or its operating profit margin of 32.6%. The disclosure is procedural in nature under SEBI LODR regulations.

ESG Rating of 70 assigned by NSE Sustainability Ratings and Analytics Limited
Rating provider is a SEBI-registered ESG Rating Provider (ERP)
Disclosure follows SEBI Master Circular dated 30th January, 2026
Company maintains a TTM revenue base of ₹13,980 Cr as of FY26

💡 Investors should treat this as a transparency-related update. Watch for any future impact on institutional fund inflows or potential ESG-linked borrowing cost benefits, though none are immediate.

Torrent Pharma Seeks Approval for Appointment of Shanti Ekambaram as Independent Director

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 05 Aug 2026, 05:43 PM

Torrent Pharmaceuticals has issued a postal ballot notice to seek shareholder approval for the appointment of Shanti Ekambaram as an Independent Director for a 3-year term. Ms. Ekambaram, a former Deputy Managing Director at Kotak Mahindra Bank, brings 39 years of experience in financial services and governance. The e-voting period is scheduled from August 8, 2026, to September 6, 2026, with results to be announced by September 8, 2026. This appointment follows her initial induction as an Additional Director on July 30, 2026.

Appointment of Shanti Ekambaram as Independent Director for a 3-year term effective July 30, 2026.
E-voting period spans 30 days, starting August 8 and ending September 6, 2026.
The appointee has 39 years of financial services experience, including a 35-year tenure at Kotak Mahindra Bank.
Cut-off date for determining shareholder voting eligibility was July 31, 2026.
Ms. Ekambaram has received ₹ 1 lakh in sitting fees since her initial board induction.

💡 Investors should note the voting timelines and monitor the announcement of results on or before September 8, 2026, to confirm the formalization of this board appointment.

Torrent Pharma Releases Q1 FY26-27 Earnings Call Transcript

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Aug 2026, 12:25 PM

Torrent Pharmaceuticals has released the official transcript of its conference call with analysts regarding the financial results for the quarter ended June 30, 2026. This filing follows the initial results announcement made on July 17, 2026. The transcript provides detailed management commentary on the company's performance, including its 32.6% operating margins and the ongoing integration of JB Chemicals. It serves as a primary source for understanding the company's strategy in the Indian chronic market and US formulations.

Transcript covers the financial performance for the quarter ended 30th June, 2026
Follows the previous board meeting and results announcement dated 17th July, 2026
Provides context on the JB Chemicals acquisition, which has an equity valuation of ₹25,689 Cr
Management discusses the TTM revenue of ₹13,980 Cr and its 5th rank in the Indian pharma market

💡 Investors should review the transcript specifically for management's commentary on the USFDA status of Dahej and Indrad facilities and the synergy realization timeline for the JB Chemicals acquisition.

Ameera Shah Ceases to be Independent Director Following Completion of Term

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 01 Aug 2026, 09:26 PM

Torrent Pharmaceuticals has announced that Ameera Shah (DIN: 00208095) ceased to be an Independent Director effective August 1, 2026. This change follows the completion of her scheduled term as per the company's previous intimation on July 30, 2026. This is a routine board rotation for the Rs 1,65,124 Cr market cap company and does not impact daily operations or financial performance. Investors should note this as a standard corporate governance procedure.

Ameera Shah completed her term as Independent Director on August 1, 2026
The cessation was previously intimated to exchanges on July 30, 2026
The change is effective as of the close of business on August 1, 2026
Torrent Pharma maintains a significant market cap of Rs 1,65,124 Cr

💡 No action is required; investors may monitor future filings for the appointment of a new Independent Director to maintain board strength.

June 30, 2026: Torrent Pharma Releases Q1 FY27 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Jul 2026, 07:34 PM

Torrent Pharmaceuticals has published the audio recording of its analyst and investor conference call for the quarter ended June 30, 2026. This is a standard regulatory disclosure following the company's recent financial results. The call provides qualitative insights into the company's TTM revenue of ₹13,980 Cr and its industry-leading operating margins of 32.6%. Investors can access the recording via the company's website to understand management's strategy regarding the ₹25,689 Cr JB Chemicals acquisition and debt management.

Audio recording for the quarter ended June 30, 2026, is now available for public review.
The call follows a period where the company reported a TTM revenue of ₹13,980 Cr.
Management commentary likely focuses on the integration of the ₹25,689 Cr JB Chemicals acquisition.
The company continues to manage a significant debt load of ₹14,277 Cr as of the latest reporting period.
Operating profit margins remain a key focus area, currently standing at 32.6%.

💡 Investors should listen to the recording specifically for updates on the JB Chemicals integration timeline and management's plan to reduce the 1.69 debt-to-equity ratio.

3 Senior Management Personnel Cease to be SMPs due to Reporting Structure Change

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 30 Jul 2026, 05:02 PM

Torrent Pharmaceuticals has announced that Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni have ceased to be designated as Senior Management Personnel (SMP) effective July 30, 2026. The company clarified that this change is due to a revision in the internal reporting structure rather than resignations or removals. This administrative reclassification occurs against the backdrop of a company with a Rs 1,65,124 Cr market cap and TTM revenue of Rs 13,980 Cr. Such changes are often procedural to align with SEBI's specific definitions of SMPs following organizational restructuring.

3 Senior Management Personnel ceased their SMP designations effective July 30, 2026
The change is attributed specifically to a 'change in reporting structure'
Torrent Pharma maintains a high OPM of 32.6% on TTM revenue of Rs 13,980 Cr
The company is currently integrating the JB Chemicals acquisition valued at Rs 25,689 Cr

💡 Investors should treat this as a procedural administrative update. Watch for any subsequent announcements regarding new appointments or further organizational changes that might signal a shift in operational strategy.

55% Revenue Growth in Q1 FY27; Torrent Pharma Integrates JB Chemicals Acquisition

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jul 2026, 04:52 PM

Torrent Pharma reported a robust 55% YoY revenue growth to ₹4,921 Cr for Q1 FY27, largely driven by the integration of JB Chemicals. Operating EBITDA surged 61% to ₹1,664 Cr with margins expanding to 33.8%, up from 32.5% YoY. However, PAT growth was restricted to 3% YoY (₹566 Cr) due to a significant spike in finance costs (₹293 Cr vs ₹45 Cr) and depreciation following the acquisition. The India business grew 60% YoY, with the company now ranking #1 in the Indian cardiac market.

Consolidated revenue increased 55% YoY to ₹4,921 Cr, with the base business growing 17% to ₹3,720 Cr.
Operating EBITDA grew 61% YoY to ₹1,664 Cr, achieving a high margin of 33.8%.
India revenues reached ₹2,890 Cr (up 60% YoY), outperforming the Indian Pharmaceutical Market (IPM) growth of 12%.
US revenues grew 36% YoY to ₹418 Cr, driven by new launches and market share gains.
Finance costs rose sharply to ₹293 Cr from ₹45 Cr YoY, reflecting the debt-funded acquisition of JB Chemicals.

💡 Investors should monitor the company's deleveraging progress as high interest costs are currently masking strong operational performance at the PAT level. Watch for the resolution of supply disruptions in Germany and the approval status of 58 products currently under ANVISA review in Brazil.

55% Revenue Growth in Q1 FY27; JB Chemicals Consolidation Drives Performance

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jul 2026, 04:50 PM

Torrent Pharma reported a 55% YoY surge in consolidated revenue to ₹4,921 Cr for Q1 FY27, primarily driven by the integration of JB Chemicals. Operating EBITDA grew 61% to ₹1,664 Cr with margins expanding to 33.8%, reflecting strong operational leverage. However, Net Profit (PAT) grew only 3% to ₹566 Cr as the bottom line was weighed down by significantly higher finance costs (₹293 Cr vs ₹45 Cr) and depreciation following the acquisition. The India business remains the core driver, now contributing ₹2,890 Cr to the total revenue.

Consolidated Revenue reached ₹4,921 Cr, a 55% increase over Q1 FY26, including JB Chemicals' contribution.
Operating EBITDA margin improved to 33.8% from 32.5% YoY, showing enhanced profitability in the base business.
India business revenue grew 60% YoY to ₹2,890 Cr, with Torrent now ranked 1st in the Indian Cardiac market.
US revenues increased by 36% to ₹418 Cr, driven by new launches and market share gains.
Finance costs surged to ₹293 Cr from ₹45 Cr YoY, reflecting the debt servicing for the ₹25,689 Cr JB Chemicals acquisition.

💡 Investors should monitor the company's deleveraging progress and the realization of cost synergies from the JB Chemicals integration, while watching for any further supply disruptions in the German market.

Torrent Pharma Appoints Veteran Banker Shanti Ekambaram as Independent Director for 3-Year Term

🟢 POSITIVE ⭐ 4/10

MANAGEMENT 📅 28 Jul 2026, 09:37 AM

Torrent Pharmaceuticals has appointed Shanti Ekambaram as an Additional Independent Director for a three-year term effective July 30, 2026. Ms. Ekambaram is a highly distinguished leader with 39 years of experience in financial services, including a long tenure as Deputy Managing Director at Kotak Mahindra Bank. Her expertise in capital markets, governance, and digital banking is expected to strengthen board-level oversight. This appointment comes as the company manages a significant debt of ₹14,277 Cr and continues the integration of its ₹25,689 Cr JB Chemicals acquisition.

Appointment is for a 3-year consecutive term starting July 30, 2026.
Appointee Shanti Ekambaram brings 39 years of financial services experience.
She previously served as Deputy Managing Director and Whole-time Director at Kotak Mahindra Bank (2022-2025).
She pioneered India's first book-building IPO transaction in 1999 for Hughes Software.
The appointment is subject to the approval of the company's shareholders.

💡 Investors should watch for the formal shareholder approval of this appointment and observe if her expertise influences the company's future capital allocation or debt management strategies.

4.19 Cr new shares of Torrent Pharma to trade from July 28 following JB Chemicals merger

🟢 POSITIVE ⭐ 9/10

M&A 📅 27 Jul 2026, 07:06 PM

Torrent Pharmaceuticals has received final listing and trading approval for 4,19,22,416 new equity shares issued to the shareholders of J.B. Chemicals & Pharmaceuticals Limited. These shares, issued pursuant to a Scheme of Amalgamation, will be admitted for trading on the NSE and BSE starting July 28, 2026. This marks the final procedural step in the massive Rs 25,689 Cr valuation merger, which significantly scales Torrent's presence in the cardiology and gastrointestinal segments. The new issuance represents a meaningful expansion of the equity base following the record date of July 17, 2026.

4,19,22,416 fully paid-up equity shares of Rs 5 each approved for listing and trading
Trading commencement date set for July 28, 2026, on both NSE and BSE
Merger involves J.B. Chemicals & Pharmaceuticals, valued at an equity valuation of Rs 25,689 Cr
Record date for the allotment of these shares was Friday, July 17, 2026
Post-merger promoter holding stands at 60.8% as of July 2026

💡 Investors should now focus on the operational integration of JB Chemicals and the realization of cost synergies to support the current 32.6% OPM. Monitor upcoming quarterly results for the first full consolidated financial performance of the merged entity.

View All TORNTPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenues grew 7% to INR 11,516 Cr in FY25. In Q2 FY26, India business grew 12% to INR 1,820 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%. US business grew 26% in Q2 FY26, while Brazil grew 21% (13% in constant currency). Germany grew 5% in Q2 FY26, though it declined 5% in constant currency due to supply disruptions.

Geographic Revenue Split

India is the largest market contributing 55% of total revenue (INR 6,393 Cr in FY25). Branded markets collectively accounted for 73% of overall revenue in Q2 FY26. Other key regions include Brazil, Germany, and the USA.

Profitability Margins

Gross Profit margin improved to 76% in FY25 from 75% in FY24. Net profit margin (adjusted for exceptions) stood at 16.6% in FY25 compared to 15.4% in FY24. Profit After Tax (PAT) grew 15.4% to INR 1,911 Cr in FY25 from INR 1,656 Cr in FY24.

EBITDA Margin

Operating EBITDA margin was 32% in FY25 (INR 3,721 Cr), up from 31% (INR 3,368 Cr) in FY24. For Q2 FY26, the EBITDA margin further improved to 32.8% (INR 1,083 Cr), representing a 15% YoY growth in EBITDA value.

Capital Expenditure

Total R&D expenditure, including capital expenses, was INR 431.53 Cr in FY25. The company also maintains an enabling resolution to raise funds through a Qualified Institutional Placement (QIP) for large acquisitions like JB Chemicals.

Credit Rating & Borrowing

The company reduced borrowings by INR 911 Cr in FY25. Net leverage (Net Debt to EBITDA) improved from 0.62x in FY25 to 0.45x in Q2 FY26. ICRA notes that leverage may rise to ~2.2x by March 2027 following the JB Chemicals acquisition, which is being funded entirely through debt.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (API) and other formulation materials are the primary inputs. While specific % of total cost per material is not disclosed, Gross Profit margin of 76% indicates raw material costs are approximately 24% of revenue.

Import Sources

Sourced from both domestic and foreign suppliers to support global manufacturing operations across India, Germany, and Brazil.

Key Suppliers

Not specifically named, but the company utilizes both in-house API manufacturing and third-party vendors. A disruption at a specific third-party supplier in Germany caused a 5% constant currency revenue decline in that market in Q2 FY26.

Capacity Expansion

The company operates key manufacturing facilities at Dahej and Indrad. Future growth is tied to the integration of JB Chemicals' manufacturing operations and supply chains to capture cost synergies.

Raw Material Costs

Raw material costs are managed through alternate sourcing strategies and vertical integration. Gross profit increased by 9% YoY to INR 8,740 Cr in FY25, reflecting efficient procurement despite a 7% revenue increase.

Manufacturing Efficiency

Efficiency is driven by increasing operating leverage and cost control. Operating margins improved to 32.2% in 9M FY25 from 29.5% in FY23 due to better capacity utilization and branded market focus.

Logistics & Distribution

Distribution is managed through a global footprint; logistics optimization and rate contracts with vendors are used to rationalize costs.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

Growth is driven by the acquisition of JB Chemicals (INR 25,689 Cr valuation) to gain scale in cardiology and gastro segments. In India, the company targets outperforming the IPM through its chronic business (currently growing at 13%). US growth is expected to accelerate following USFDA EIR/VAI status at Dahej and Indrad, enabling more than the previous 2 launches per year.

Products & Services

Branded and generic pharmaceutical formulations in therapeutic segments including Cardiovascular (CVS), Gastrointestinal (GI), Central Nervous System (CNS), and vitamins/nutrients.

Brand Portfolio

Torrent Pharma, Heumann Pharma (Germany), and soon-to-be-integrated brands from JB Chemicals and Pharmaceuticals.

New Products/Services

New launches in India and the US are key drivers; US growth of 26% in Q2 FY26 was significantly aided by new product volume and market share gains.

Market Expansion

Expansion is focused on branded generic markets (India, Brazil, SE Asia) and strengthening the German tender business. The JB Chemicals acquisition expands the footprint in India and South Africa.

Market Share & Ranking

Torrent is the 5th largest player in the Indian pharmaceutical market. It has achieved target market shares in new US launches.

Strategic Alliances

Acquisition of a 46.39% stake in JB Chemicals from KKR for INR 11,917 Cr, followed by a mandatory open offer for 26% and an eventual merger.

🌍 External Factors

Industry Trends

The industry is shifting toward branded generics and chronic therapies to ensure stable cash flows. Torrent is positioned as a leader in this shift, with 73% of revenue from branded markets.

Competitive Landscape

Competes with large Indian pharma players and global generic companies. Competition in the US generics market remains intense with persistent price erosion.

Competitive Moat

Moat is built on a strong field force in India/Brazil, high entry barriers in chronic segments, and a proven track record of integrating acquisitions. These are sustainable due to the long-term nature of chronic prescriptions.

Macro Economic Sensitivity

Sensitive to healthcare spending trends and regulatory changes in India and Brazil. Inflation impacts SG&A expenses, which were INR 4,438 Cr (39% of revenue) in FY25.

Consumer Behavior

Increasing demand for chronic disease management (cardiac, gastro) drives steady volume growth in the India business.

Geopolitical Risks

Operations in Russia (Zao Torrent Pharma) and other emerging markets expose the company to regional political instability and trade barriers.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA manufacturing standards (cGMP) and price controls (DPCO in India). Dahej and Indrad facilities are currently under VAI (Voluntary Action Indicated) status.

Environmental Compliance

The company has instituted an ESG framework with four pillars: responsible consumption, practices, communication, and supply chain. It carries significant cyber security insurance.

Taxation Policy Impact

Effective tax rate was approximately 28.5% in FY25 (INR 762 Cr tax on INR 2,673 Cr PBT). The company faces potential tax exposure from cross-border transactions and varying international laws.

Legal Contingencies

Ongoing product liability litigation in the US regarding Losartan and Valsartan. One pending complaint from the Curatio merger was also noted.

⚠️ Risk Analysis

Key Uncertainties

Integration risk of the JB Chemicals acquisition (INR 25,689 Cr value) is a medium-term uncertainty. USFDA regulatory status of manufacturing plants can impact 10-15% of revenue if escalations occur.

Geographic Concentration Risk

High concentration in India (55% of revenue). Any regulatory change in the Indian Pharmaceutical Market (IPM) significantly impacts the consolidated profile.